OKYO Pharma (OKYO) Debt to Equity (2023 - 2025)

OKYO Pharma (OKYO) has 3 years of Debt to Equity data on file, last reported at -$0.15 in Q1 2025.

• Debt to Equity for Q1 2025 came in at -$0.15, down 153.81% year-over-year; the trailing twelve-month figure through Mar 2025 was -$0.15 (down 153.81% YoY), and the FY2025 annual result was -$0.15, down 153.81% from the prior year.
• Debt to Equity declined to -$0.15 in Q1 2025 per OKYO's latest filing, from -$0.0 in the prior quarter.
• Over five years, Debt to Equity peaked at $0.0 in Q3 2023 and troughed at -$0.15 in Q1 2025.
• A 3-year average of -$0.05 and a median of -$0.03 in 2024 frame the typical range for Debt to Equity.
• The sharpest annual moves came in 2024 and 2025: Debt to Equity plunged 100.33% in 2024, then sank 153.81% in 2025.
• A 3-year view of Debt to Equity shows it stood at $0.0 in 2023, then sank by 100.33% to -$0.0 in 2024, then sank by 1243487.77% to -$0.15 in 2025.
• Business Quant data shows OKYO's Debt to Equity at -$0.15 in Q1 2025, -$0.0 in Q3 2024, and -$0.06 in Q1 2024.